Klinikum Stuttgart
- Address
- lock Available on a paid plan
Oncology for pediatrics at Klinikum Stuttgart
This research area focuses on neoplasms in children, with a strong emphasis on high-risk neuroblastoma. The trials are designed to improve treatment outcomes by evaluating better ways to combine chemotherapy, radiotherapy, and immunotherapy for young patients with difficult-to-treat disease.
- Studying treatment strategies for high-risk neuroblastoma after initial therapy response
- Comparing approaches that use high-dose chemotherapy and radiotherapy to improve survival
- Assessing chemoimmunotherapy for patients with persistent metastatic disease
Overall, the work at this site aims to refine pediatric cancer care by testing more effective treatment combinations and improving outcomes for children with aggressive tumors.
Immune system processes and transplantation research
This trial area explores how the immune system can be modulated in living donor kidney transplantation. The main goal is to evaluate whether donor-derived modified immune cells can support better transplant acceptance and promote a tolerance-like response compared with standard treatment.
- Investigating kidney transplantation outcomes in recipients of living donor organs
- Testing whether immune suppression can be tailored to encourage operational tolerance
- Comparing a new cell-based approach with standard-of-care therapy
At Klinikum Stuttgart, this research reflects a broader effort to improve transplant success while reducing the need for long-term immune suppression.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 18 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Institut Gustave Roussy1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Stuttgart
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Irinotecan, Ifosfamide, Vincristine, and Dactinomycin in Frontline and Relapsed Rhabdomyosarcoma in Pediatric and Adult Populations | The University Of Birmingham | Phase I | Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 18 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 2 | Unknown | 2020-10-07 | 2024-11-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.